#United States #NASDAQ #Biopharmaceutical #Bridgewater #Insmed Incorporated

Insmed's Recent Grant of Inducement Awards

Insmed Incorporated, a global biopharmaceutical company committed to delivering transformative therapies, has recently reported significant inductions under the NASDAQ Listing Rule 5635(c)(4). On September 5, 2025, Insmed confirmed that it awarded inducement grants to 115 new employees as part of their hiring strategy. This initiative demonstrates Insmed's commitment to attracting talent while striving to meet the avant-garde standards in the biopharmaceutical sector.

Details of the Inducement Grants

As part of the inducement strategy, the newly appointed employees received a total of 70,742 restricted stock units alongside options to buy 8,420 shares of the company's stock. The stock options were issued at an exercise price of $136.10 per share, reflecting the market closing on the grant date at the NASDAQ Global Select Market. This strategic allocation of equity not only incentivizes new hires but positions the firm to foster a long-term dedication among its personnel.

The structure of these inducements is carefully crafted. The restricted stock units will roll out under a four-year vesting schedule, allowing 25% of the shares to vest on each anniversary following the grant's initiation. This encourages continued engagement from employees, solidifying their bond with Insmed during their tenure.

In parallel, the options to purchase shares also adopt a ten-year term with a vesting stipulation, allowing 25% of the shares to vest after the first year, followed by 12.5% every six months thereafter for a total of four years, again contingent on continued employment with the company. The provisions of these grants reflect Insmed’s dedication to securing top talent that aligns with its mission to combat serious health issues through innovation and dedication.

About Insmed

Founded with a people-first ethos, Insmed operates with the vision of creating first- and best-in-class therapies, primarily targeting chronic and debilitating conditions, especially in pulmonary and inflammatory diseases. The firm is at the forefront of advancing various approved medicines while continuing to extensively research both mid- and late-stage investigational programs. Furthermore, Insmed emphasizes cutting-edge drug discovery, including methods like gene therapy and AI-driven approaches to revolutionize medicine.

Operating from its headquarters in Bridgewater, New Jersey, Insmed boasts a global presence, with research facilities located not only in the United States but also across Europe and Japan. This international footprint and its commitment to patient-centered care affirm Insmed's status as a leading employer in the biopharmaceutical industry, having secured accolades, including top rankings from Science for consecutive years.

For those keen to learn more about Insmed's initiatives, therapeutic advancements, and workplace culture, additional information is readily available on their official website as well as through various professional social media channels.

Conclusion

In summary, Insmed Incorporated's recent inducement awards reflect a significant commitment to its workforce and its operational values. By effectively incentivizing new talent through equity participation and structured vesting, Insmed positions itself as a dynamic player in the biopharmaceutical landscape, poised for innovative strides in combating critical health challenges.

For further inquiries regarding investment opportunities or corporate communications, you can reach out to:
Bryan Dunn, Vice President, Investor Relations (646) 812-4030
Claire Mulhearn, Vice President, Corporate Communications (862) 842-6819